Current Problems and the Future of Antiretroviral Drug Trials
- 25 April 1997
- journal article
- editorial
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 276 (5312) , 548-550
- https://doi.org/10.1126/science.276.5312.548
Abstract
Now that a growing arsenal of new and potential anti-HIV drugs exists, debate and discussion about the optimal way to test and use these drugs has begun. In his Policy Forum, Joep Lange, director of the National AIDS Therapy Evaluation Centre in Amsterdam, takes the controversial stand that suboptimal therapies and drug trial designs are still being used. He discusses the underlying reasons for this situation and the challenges for the future.Keywords
This publication has 15 references indexed in Scilit:
- The Effect on Human Immunodeficiency Virus Type 1 RNA Levels in Cerebrospinal Fluid after Initiation of Zidovudine or DidanosineThe Journal of Infectious Diseases, 1997
- Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of DefectsScience, 1996
- HIV TherapeuticsScience, 1996
- Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in PlasmaScience, 1996
- VirologyAIDS, 1996
- Pharmacokinetic, Safety, and Antiviral Profiles of Oral Ganciclovir in Persons Infected with Human Immunodeficiency Virus: A Phase I/II StudyThe Journal of Infectious Diseases, 1995
- Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC)The Journal of Infectious Diseases, 1995
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- A Randomized Pilot Study of Alternating or Simultaneous Zidovudine and Didanosine Therapy in Patients with Symptomatic Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1994